Open sidebar
Focus
Aduhelm
Dementia & Alzheimer's
|
George Citroner
Controversial Alzheimer’s Drug Aduhelm Dropped by Drugmaker After Doubtful Data and Denied Coverage
The drug was discontinued by Biogen after inconsistent trial data, concerning side effects including brain swelling, and poor financial outlook.
Feb 01, 2024
|
George Citroner
Feb 01
|
Dementia & Alzheimer's
|
George Citroner
Many Ineligible for New Alzheimer’s Drugs: Study
Aug 28, 2023
|
George Citroner
Aug 28
|
US News
|
Katabella Roberts
FDA’s Approval Process of Controversial Alzheimer’s Drug Was ‘Rife With Irregularities’: Congressional Probe
Dec 30, 2022
|
Katabella Roberts
Dec 30
|
Policies & Impacts
|
Katabella Roberts
Biden Touts Reduction of 2023 Medicare Fees, Due Largely to Limiting of Alzheimer’s Drug
Sep 28, 2022
|
Katabella Roberts
Sep 28
|
Medicine
|
Health 1+1
,
Kelly Song
Health: What Patients Need to Know About the Controversial Alzheimer's Drug Aducanumab
Aug 20, 2022
|
Health 1+1
Aug 20
|
Health Care
|
Marina Zhang
Fixed Packaging of Alzheimer’s Drug May Waste $605 Million a Year for Medicare, Experts Warn
Jul 06, 2022
|
Marina Zhang
Jul 06
|
Companies
|
Reuters
Biogen CEO to Step Down, Drugmaker Pulls Back on Alzheimer’s Drug Aduhelm
May 04, 2022
|
Reuters
May 04
|
Health News
|
Zachary Stieber
Medicare Officially Limits Coverage of Alzheimer’s Drug to Those in Clinical Trials
Apr 08, 2022
|
Zachary Stieber
Apr 08
|
Executive Branch
|
Zachary Stieber
Biden Administration Decides to Limit Medicare Coverage of New Alzheimer’s Drug
Jan 11, 2022
|
Zachary Stieber
Jan 11
|
Executive Branch
|
Zachary Stieber
CMS May Review Medicare Premium in Light of Aduhelm Price Drop
Jan 10, 2022
|
Zachary Stieber
Jan 10
|
Health
|
Reuters
Biogen Halves Price of Alzheimer’s Drug to $28,200
Dec 20, 2021
|
Reuters
Dec 20
|